Retail
OKLAHOMA CITY -- CVS (CVS) knows how to strike - and win -- a deal.
Granted, in its current quest for Longs Drug Stores (LDG), CVS now faces some pesky competition from rival Walgreen (WAG), which offered $75 a share for Longs just three days before CVS's own $71.50-a-share tender offer was set to expire. Unable to win enough support for its lower bid - and unwilling, for now, to raise it any higher - CVS has given Longs shareholders another month to make up their minds. Ultimately, CVS tends to get its way. Last time around, the company overcame a higher bid from rival Express Scripts (ESRX) to win control of Caremark despite investor outrage. Less than 18 months after that deal closed, CVS adopted a similar approach with Longs. In both cases, CVS promised rich payouts to its target's top executives and secured attractive buyout prices -- sheltered by strict deal-protection measures -- in return. Of course, Caremark shareholders fought back and forced CVS to repeatedly raise its bid. From the start, Longs shareholders have aimed to do the same. "The (Longs) board -- well aware of the material insider benefits the Caremark board secured via its sale to CVS -- was eager to cater a sale of the company to CVS in order to receive similar benefits and to secure lucrative change-in-control payments that board members and management would not have received absent the proposed buyout," shareholders claimed in one of two class-action lawsuits they recently settled with the company. "Accordingly, the board catered the sales process exclusively to CVS and made no attempts to adequately canvas the market to ensure that they were securing the best possible price for the company's shares."TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet